T-Cell Technology & Development
The IL-7 project was founded in the early 2000s by a French team under the name of Cytheris. It was resumed in 2013 by US investors.
Early support came from numerous academic and public organizations with collaboration at preclinical and clinical levels: NCI, NIAID, INSERM, MSKCC, FHCRC, ANRS, Institut Pasteur.
More than 60 international publications have been produced.
The project is currently involved in many international collaborations for the clinical development of IL-7 immunotherapy in Oncology and Infectious diseases.
IL-7 provides a global T-cell support for Immunotherapies
RevImmune is Headquartered in Bethesda, Maryland, USA, with a fully operational subsidiary in Paris, France
DVM, MSc, C.S.O.
Chief Scientific Officer of RevImmune.
Ex Postdoctoral fellow at MIT, Ex-innovation Director at Sanofi, Founder past President and Chief Executive Officer of Cytheris (until 10/2011)
MSc Health Sciences, D.C.O.
Director of Clinical Operations at RevImmune
With a past experience of clinical development at Pfizer, Organon, Quintiles
MSc PhD, D.P.D
Director of Process Development
ex Postdoctoral fellow at LSCG “CNRS” - Nancy I. Anne has a 20 years experience of biotech process development mainly at Cytheris and then RevImmune.
Deputy Director of Process Development
Ex project manager and team leader at Glenmark and Ablynx
Our project is supported by key opinion leaders from a range of universities and institutions.
Richard Hotchkiss MD
Professor of Anesthesiology Washington University School of Medicine, St Louis, MO, USA
Kenneth Remy MD
Assistant Professor of Pediatrics, Critical Care Medicine
Lyle L. Moldawer Ph.D.
Professor of Surgery Sepsis and Critical Illness Research Center University of Florida College of Medicine
Mac Cheever MD
Professor Clinical Research Division, Fred Hutch Director for the Cancer Immunotherapy Trials Network (CITN)